Cellular Senescence in Postmitotic Cells: Beyond Growth Arrest

Trends in Cell Biology

Volumn 28, Issue 8, 2018, Pages 595-607

  Sapieha, Przemyslaw ^a,b,c   Mallette, Frédérick A ^a,b,c  

^a Succursale Centre Ville   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

adipose tissue; Cellular senescence; CNS; inflammation; postmitotic; reprogramming

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ADIPOSE TISSUE; CELL AGING; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL SURVIVAL; DIABETIC RETINOPATHY; DNA DAMAGE RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; MITOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETINA GANGLION CELL; RETROLENTAL FIBROPLASIA; REVIEW; ANIMAL; APOPTOSIS; CELL PROLIFERATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLULAR SENESCENCE; HUMANS; MITOSIS;

EID: 85046141200     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2018.03.003     Document Type: Review

References (136)

1. Hayflick, L., The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37 (1965), 614–636.
2. Calabrese, V., et al. SOCS1 links cytokine signaling to p53 and senescence. Mol. Cell 36 (2009), 754–767.
3. Mallette, F.A., et al. Myc down-regulation as a mechanism to activate the Rb pathway in STAT5A-induced senescence. J. Biol. Chem. 282 (2007), 34938–34944.
4. Serrano, M., et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997), 593–602.
5. Munoz-Espin, D., Serrano, M., Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15 (2014), 482–496.
6. Eggert, T., et al. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression. Cancer Cell 30 (2016), 533–547.
7. Nordling, C.O., A new theory on cancer-inducing mechanism. Br. J. Cancer 7 (1953), 68–72.
8. Dimri, G.P., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 9363–9367.
9. Herbig, U., et al. Cellular senescence in aging primates. Science, 311, 2006, 1257.
10. Jeyapalan, J.C., et al. Accumulation of senescent cells in mitotic tissue of aging primates. Mech. Ageing Dev. 128 (2007), 36–44.
11. Wang, C., et al. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell 8 (2009), 311–323.
12. Baker, D.J., et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530 (2016), 184–189.
13. Demaria, M., et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31 (2014), 722–733.
14. Munoz-Espin, D., et al. Programmed cell senescence during mammalian embryonic development. Cell 155 (2013), 1104–1118.
15. Storer, M., et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 155 (2013), 1119–1130.
16. Braig, M., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 (2005), 660–665.
17. Chen, Z., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005), 725–730.
18. Collado, M., et al. Tumour biology: senescence in premalignant tumours. Nature, 436, 2005, 642.
19. Michaloglou, C., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005), 720–724.
20. Baker, D.J., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479 (2011), 232–236.
21. Baar, M.P., et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 169 (2017), 132–147.
22. Chang, J., et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22 (2016), 78–83.
23. Childs, B.G., et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354 (2016), 472–477.
24. Hashimoto, M., et al. Elimination of p19(ARF)-expressing cells enhances pulmonary function in mice. JCI Insight, 1, 2016, e87732.
25. Jeon, O.H., et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 23 (2017), 775–781.
26. Ogrodnik, M., et al. Cellular senescence drives age-dependent hepatic steatosis. Nat. Commun., 8, 2017, 15691.
27. Roos, C.M., et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15 (2016), 973–977.
28. Schafer, M.J., et al. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun., 8, 2017, 14532.
29. Xu, M., et al. Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife, 4, 2015, e12997.
30. Yosef, R., et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun., 7, 2016, 11190.
31. Zhu, Y., et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14 (2015), 644–658.
32. Mosteiro, L., et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science, 354, 2016, aaf4445.
33. Childs, B.G., et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug Discov. 16 (2017), 718–735.
34. Farr, J.N., et al. Identification of senescent cells in the bone microenvironment. J. Bone Miner. Res. 31 (2016), 1920–1929.
35. Jurk, D., et al. Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell 11 (2012), 996–1004.
36. Oubaha, M., et al. Senescence-associated secretory phenotype contributes to pathological angiogenesis in retinopathy. Sci. Transl. Med., 8, 2016, 362ra144.
37. Wang, Y., et al. HIV-1 Vpr disrupts mitochondria axonal transport and accelerates neuronal aging. Neuropharmacology 117 (2017), 364–375.
38. Jung, T., et al. Lipofuscin: formation, distribution, and metabolic consequences. Ann. N. Y. Acad. Sci. 1119 (2007), 97–111.
39. Reichel, W., Lipofuscin pigment accumulation and distribution in five rat organs as a function of age. J. Gerontol. 23 (1968), 145–153.
40. Reichel, W., et al. Lipofuscin pigment accumulation as a function of age and distribution in rodent brain. J. Gerontol. 23 (1968), 71–78.
41. Strehler, B.L., et al. GEE MV: rate and magnitude of age pigment accumulation in the human myocardium. J. Gerontol. 14 (1959), 430–439.
42. Sitte, N., et al. Lipofuscin accumulation in proliferating fibroblasts in vitro: an indicator of oxidative stress. Exp. Gerontol. 36 (2001), 475–486.
43. Georgakopoulou, E.A., et al. Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. Aging (Albany N. Y.) 5 (2013), 37–50.
44. Evangelou, K., et al. Robust, universal biomarker assay to detect senescent cells in biological specimens. Aging Cell 16 (2017), 192–197.
45. Chopp, M., et al. Neurogenesis, angiogenesis, and MRI indices of functional recovery from stroke. Stroke 38:Suppl. 2 (2007), 827–831.
46. Joyal, J.-S., et al. Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood 117 (2011), 6024–6035.
47. Li, L., et al. Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res. 1132 (2007), 185–192.
48. Zlokovic, B.V., Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12 (2011), 723–738.
49. Yin, F., et al. Energy metabolism and inflammation in brain aging and Alzheimer's disease. Free Radic. Biol. Med. 100 (2016), 108–122.
50. Brown, W.R., Thore, C.R., Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol. Appl. Neurobiol. 37 (2011), 56–74.
51. Storkebaum, E., et al. Cerebrovascular disorders: molecular insights and therapeutic opportunities. Nat. Neurosci. 14 (2011), 1390–1397.
52. Brun, A., Englund, E., A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19 (1986), 253–262.
53. Prat, A., et al. Migration of multiple sclerosis lymphocytes through brain endothelium. Arch. Neurol. 59 (2002), 391–397.
54. Rule, R.R., et al. Gray matter perfusion correlates with disease severity in ALS. Neurology 74 (2010), 821–827.
55. Bartkova, J., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444 (2006), 633–637.
56. Di Micco, R., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444 (2006), 638–642.
57. Mallette, F.A., et al. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 21 (2007), 43–48.
58. Kreiling, J.A., et al. Age-associated increase in heterochromatic marks in murine and primate tissues. Aging Cell 10 (2011), 292–304.
59. Zhang, R., et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev. Cell 8 (2005), 19–30.
60. Coppe, J.P., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6 (2008), 2853–2868.
61. Macip, S., et al. Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J. 21 (2002), 2180–2188.
62. Freund, A., et al. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 30 (2011), 1536–1548.
63. Passos, J.F., et al. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol. Syst. Biol., 6, 2010, 347.
64. Correia-Melo, C., et al. Mitochondria are required for pro-ageing features of the senescent phenotype. EMBO J. 35 (2016), 724–742.
65. Lanza, I.R., et al. Chronic caloric restriction preserves mitochondrial function in senescence without increasing mitochondrial biogenesis. Cell Metab. 16 (2012), 777–788.
66. Binet, F., et al. Neuronal ER stress impedes myeloid-cell-induced vascular regeneration through IRE1alpha degradation of netrin-1. Cell Metab. 17 (2013), 353–371.
67. Sapieha, P., et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J. Clin. Invest. 120 (2010), 3022–3032.
68. Duh, E.J., et al. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight, 2, 2017, 93751.
69. Hartnett, M.E., Penn, J., Mechanisms and management of retinopathy of prematurity. N. Engl. J. Med. 367 (2012), 2515–2526.
70. Dejda, A., et al. Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk. J. Clin. Invest. 124 (2014), 4807–4822.
71. Moiseeva, O., et al. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Aging Cell 12 (2013), 489–498.
72. Foretz, M., et al. Metformin: from mechanisms of action to therapies. Cell Metab. 20 (2014), 953–966.
73. Howell, J.J., et al. Metformin inhibits hepatic mTORC1 dignaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 25 (2017), 463–471.
74. Heaton, R.K., et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol. 17 (2011), 3–16.
75. Moiseeva, O., et al. Mitochondrial dysfunction contributes to oncogene-induced senescence. Mol. Cell. Biol. 29 (2009), 4495–4507.
76. Jones, R.G., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18 (2005), 283–293.
77. Farr, J.N., et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat. Med. 23 (2017), 1072–1079.
78. Dallas, S.L., et al. The osteocyte: an endocrine cell.. and more. Endocr. Rev. 34 (2013), 658–690.
79. Park, D., et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell 10 (2012), 259–272.
80. Xu, M., et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E6301–E6310.
81. Aguilar, M., et al. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 313 (2015), 1973–1974.
82. Berry, R., Rodeheffer, M.S., Characterization of the adipocyte cellular lineage in vivo. Nat. Cell Biol. 15 (2013), 302–308.
83. Minamino, T., et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat. Med. 15 (2009), 1082–1087.
84. Denoyelle, C., et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell Biol. 8 (2006), 1053–1063.
85. Binet, F., Sapieha, P., ER stress and angiogenesis. Cell Metab. 22 (2015), 560–575.
86. Pereira, E.R., et al. Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF). J. Biol. Chem. 289 (2014), 3352–3364.
87. Deng, Y., et al. The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolism. J. Clin. Invest. 123 (2013), 455–468.
88. Zhou, J., et al. The crystal structure of human IRE1 luminal domain reveals a conserved dimerization interface required for activation of the unfolded protein response. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 14343–14348.
89. Hollien, J., Weissman, J.S., Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science 313 (2006), 104–107.
90. Upton, J.P., et al. IRE1alpha cleaves select microRNAs during ER stress to derepress translation of proapoptotic Caspase-2. Science 338 (2012), 818–822.
91. Dorr, J.R., et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 501 (2013), 421–425.
92. Lee, A.H., et al. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol. Cell. Biol. 23 (2003), 7448–7459.
93. Sriburi, R., et al. Coordinate regulation of phospholipid biosynthesis and secretory pathway gene expression in XBP-1(S)-induced endoplasmic reticulum biogenesis. J. Biol. Chem. 282 (2007), 7024–7034.
94. Martinon, F., et al. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat. Immunol. 11 (2010), 411–418.
95. Qiu, Q., et al. Toll-like receptor-mediated IRE1alpha activation as a therapeutic target for inflammatory arthritis. EMBO J. 32 (2013), 2477–2490.
96. Coppe, J.P., et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5 (2010), 99–118.
97. Xue, W., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007), 656–660.
98. Kang, T.W., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479 (2011), 547–551.
99. Krizhanovsky, V., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134 (2008), 657–667.
100. Dejda, A., et al. Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk. J. Clin. Invest. 124 (2014), 4807–4822.
101. Bagchi, A., et al. CHD5 is a tumor suppressor at human 1p36. Cell 128 (2007), 459–475.
102. Mallette, F.A., Richard, S., JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell Rep. 2 (2012), 1233–1243.
103. Tahara, H., et al. Increase in expression level of p21sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene 10 (1995), 835–840.
104. Kortlever, R.M., et al. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 8 (2006), 877–884.
105. He, L., et al. A microRNA component of the p53 tumour suppressor network. Nature 447 (2007), 1130–1134.
106. de Stanchina, E., et al. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13 (2004), 523–535.
107. Ferbeyre, G., et al. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14 (2000), 2015–2027.
108. Pearson, M., et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406 (2000), 207–210.
109. Bischof, O., et al. Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol. Cell. Biol. 25 (2005), 1013–1024.
110. Mallette, F.A., et al. Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 23 (2004), 91–99.
111. Agger, K., et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 23 (2009), 1171–1176.
112. Barradas, M., et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 23 (2009), 1177–1182.
113. Narita, M., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113 (2003), 703–716.
114. Yu, Y., et al. Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma. Cancer Cell 33 (2018), 322–336.
115. Wiley, C.D., Campisi, J., From ancient pathways to aging cells-connecting metabolism and cellular senescence. Cell Metab. 23 (2016), 1013–1021.
116. Kaplon, J., et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498 (2013), 109–112.
117. Aird, K.M., et al. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 3 (2013), 1252–1265.
118. Korolchuk, V.I., et al. Mitochondria in cell senescence: is mitophagy the weakest link?. EBioMedicine 21 (2017), 7–13.
119. Mallette, F.A., Ferbeyre, G., The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 6 (2007), 1831–1836.
120. Yang, H.S., Hinds, P.W., Increased ezrin expression and activation by CDK5 coincident with acquisition of the senescent phenotype. Mol. Cell 11 (2003), 1163–1176.
121. Hoare, M., et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat. Cell Biol. 18 (2016), 979–992.
122. Kuilman, T., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133 (2008), 1019–1031.
123. Rodier, F., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11 (2009), 973–979.
124. d'Adda di Fagagna, F., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426 (2003), 194–198.
125. Acosta, J.C., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133 (2008), 1006–1018.
126. Wajapeyee, N., et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132 (2008), 363–374.
127. Chien, Y., et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 25 (2011), 2125–2136.
128. Herranz, N., et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat. Cell Biol. 17 (2015), 1205–1217.
129. Laberge, R.M., et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 17 (2015), 1049–1061.
130. Narita, M., et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science 332 (2011), 966–970.
131. Kang, C., et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science, 349, 2015, aaa5612.
132. Acosta, J.C., et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15 (2013), 978–990.
133. Chiche, A., et al. Injury-induced senescence enables in vivo reprogramming in skeletal muscle. Cell Stem Cell 20 (2017), 407–414.
134. Ritschka, B., et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev. 31 (2017), 172–183.
135. Coppe, J.P., et al. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem. 281 (2006), 29568–29574.
136. Sapieha, P., Eyeing central neurons in vascular growth and reparative angiogenesis. Blood 120 (2012), 2182–2194.